• Mashup Score: 8
    Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance - 2 year(s) ago

    Treatment for acute myeloid leukemia (AML) has evolved rapidly over the last decade as improved understanding of cytogenetic and molecular drivers of leukemogenesis refined survival prognostication and enabled development of targeted therapeutics. Molecularly targeted therapies are now approved for the treatment of FLT3 and IDH1/2-mutated AML and additional molecularly and cellularly targeted…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of smbenlazar
      smbenlazar

      Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance https://t.co/K0sn1kflOL #mdpicancers via @Cancers_MDPI https://t.co/9uP0z4GS9r

  • Mashup Score: 11
    Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment - 2 year(s) ago

    Extranodal Marginal Zone Lymphoma (EMZL lymphoma) is an indolent B-cell lymphoma with a median age at diagnosis of about 60 years. It accounts for 7–8% of all B-cell lymphomas. It can occur in various extranodal sites, including stomach, lung, ocular adnexa, and skin; furthermore, the disseminated disease can be found in 25–50% of cases. Several infectious agents, such as Helicobacter pylori (H….

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of smbenlazar
      smbenlazar

      Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment https://t.co/8O6SBZBVFN #mdpicancers via @Cancers_MDPI #lymsm https://t.co/Mj385QPgNZ

  • Mashup Score: 0
    Emerging Therapies in CLL in the Era of Precision Medicine - 2 year(s) ago

    Over the past decade, the treatment landscape of CLL has vastly changed from the conventional FC (fludarabine and cyclophosphamide) and FCR (FC with rituximab) chemotherapies to targeted therapies, including inhibitors of Bruton tyrosine kinase (BTK) and phosphatidylinositol 3-kinase (PI3K) as well as inhibitors of BCL2. These treatment options dramatically improved clinical outcomes; however,…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of smbenlazar
      smbenlazar

      Emerging Therapies in CLL in the Era of Precision Medicine https://t.co/1sU54uRzNY #mdpicancers via @Cancers_MDPI #CLL #leusm https://t.co/ekQElGW9tG

  • Mashup Score: 4
    Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary? - 2 year(s) ago

    Acquiring sufficient data is imperative to accurately predict tumor growth dynamics and effectively treat patients. The aim of this study was to investigate the number of volume measurements necessary to predict breast tumor growth dynamics using the logistic growth model. The model was calibrated to tumor volume data from 18 untreated breast cancer patients using a varying number of measurements…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ara_anderson
      ara_anderson

      RT @HeikoEnderling: Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary? https://t.co/eFeltbK0uu #mdpicancers v…

  • Mashup Score: 1
    Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary? - 2 year(s) ago

    Acquiring sufficient data is imperative to accurately predict tumor growth dynamics and effectively treat patients. The aim of this study was to investigate the number of volume measurements necessary to predict breast tumor growth dynamics using the logistic growth model. The model was calibrated to tumor volume data from 18 untreated breast cancer patients using a varying number of measurements…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dbasanta
      dbasanta

      RT @HeikoEnderling: Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary? https://t.co/eFeltbK0uu #mdpicancers v…

  • Mashup Score: 0
    Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment - 2 year(s) ago

    Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with systemic toxicity. Multimodal treatment combinations can help improve patient outcomes; however, implementation is limited by additive toxicities…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dsmgyo
      dsmgyo

      #TumorTreatingFields (TTFields) Therapy Concomitant with #Taxanes for #Cancer Treatment https://t.co/erE0fiD32t #mdpicancers via @Cancers_MDPI @Novocure @novocureclinops https://t.co/nCfVB47e6N

  • Mashup Score: 0
    Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre - 2 year(s) ago

    Introduction: Stereotactic ablative body radiotherapy (SABR) offers patients with stage I non-small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introducing SABR at a Scottish regional cancer centre was studied. Methods: The Edinburgh Cancer Centre Lung Cancer Database was assessed. Treatment patterns and outcomes were compared across treatment groups (no…

    Source: MDPI
    Categories: Latest Headlines, Oncologists2
    Tweet Tweets with this article
    • Profile photo of PeterHall001
      PeterHall001

      Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre https://t.co/WyP8d5ud0c #mdpicancers via @Cancers_MDPI

  • Mashup Score: 1
    NPM 1 Mutations in AML—The Landscape in 2023 - 2 year(s) ago

    Acute myeloid leukemia (AML) represents 80% of acute leukemia in adults and is characterized by clonal expansion of hematopoietic stem cells secondary to genomic mutations, rendering a selective growth advantage to the mutant clones. NPM1mut is found in around 30% of AML and clinically presents with leukocytosis, high blast percentage and extramedullary involvement. Considered as a “gate-keeper”…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of smbenlazar
      smbenlazar

      NPM 1 Mutations in AML—The Landscape in 2023 https://t.co/2bbQrsu3Tj #mdpicancers via @Cancers_MDPI #leusm https://t.co/rf3ZrOW23p

  • Mashup Score: 1
    Fear of Cancer Recurrence in Patients with Sarcoma in the United Kingdom - 2 year(s) ago

    Fear of cancer recurrence (FCR) is a persistent concern among those living with cancer and is associated with a variety of negative psychosocial outcomes. However, people with sarcoma have been underrepresented within this area of research. We aimed to determine the prevalence of FCR experienced by people with sarcoma in the United Kingdom and explore factors that may predict FCR, such as the…

    Source: MDPI
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of crisbergerot
      crisbergerot

      RT @cancer_K2A: Fear of Cancer Recurrence in Patients with Sarcoma in the United Kingdom https://t.co/XS2vXsTqQW #mdpicancers via @Cancers_…

Load More